Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Pancreatic Neoplasms

Pancreatic Neoplasms, Thromboembolism

Urinary Bladder Neoplasms

Ovarian Neoplasms

Cholangiocarcinoma

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Pancreatic Neoplasms

Locally Advanced Pancreatic Cancer

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Lymphoma, T-Cell, Peripheral

Pancreatic Neoplasms

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Nasopharyngeal Carcinoma

Stomach Neoplasms

Nasopharyngeal Carcinoma

Lymphoma, Extranodal NK-T-Cell

Pancreatic Neoplasms

Gallbladder Neoplasms

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

Lymphoma, Large B-Cell, Diffuse

Pancreatic Neoplasms

Hypoxia, Pancreatic Neoplasms

Infiltrating Bladder Urothelial Carcinoma

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Urinary Bladder Neoplasms, Recurrence

Pancreatic Neoplasms

Uterine Neoplasms

Pancreatic Neoplasms

Osteosarcoma

Pancreatic Neoplasms

Pancreatic Neoplasms

Pancreatic Neoplasms

Urinary Bladder Neoplasms

Pancreatic Neoplasms, Malnutrition

Pancreatic Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular, Neoplasm Metastasis, Recurrence

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

SLAT

PARC

LUNG-05

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

GETUGV04

SCENIC

Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma

A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers

A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.

Clinical Study Evaluating the Effect of Losartan

NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Safety and Efficacy of Scheduled Intravesical Gemcitabine Versus Intravesical BCG for Intermediate and High Risk Non Muscle Invasive Bladder Cancer: A Prospective, Randomized Study

Chi-GVM Regimen for the Treatment of R/R PTCL

Canagliflozin With Gemcitabine in Pancreatic Carcinoma

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma

Pilot Study of Antiviral Treatment in Combination With Low-dose Gemcitabine in EBV-associated Gastric Cancer (EBVaGC)

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma

GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma

Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer

Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma

Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy

Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer

Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

PELICAN

MIPA

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

PC02

PC01

Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer

SLOWDOSE001

Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus

Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer

Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy

Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

DO201001

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer